Precision, speed, and turn-key brain imaging for the indications we're working in — built on a peer-reviewed method.
Millimeter-level functional measurement, calibrated to the person and the scanner.
From scan to calibrated report in days, not months.
IRB-ready, end to end: scheduling → acquisition → neuroAI analysis.
EyeThree is collaborating with PREVENT-AD, one of the largest Alzheimer’s deep-phenotyping studies in the world. Led at the Montreal Neurological Institute, PREVENT-AD is a multi-modal, longitudinal study of adults at elevated risk for cognitive decline — including a familial-risk cohort with a parent who has Alzheimer’s disease.
Across repeated visits, participants complete quantitative MRI (the npMRI acquisition), a full neuropsychological battery, and, for a subset, biological samples — cerebrospinal fluid, plasma, and amyloid-β and tau PET. It is the first study to capture the transition from normal cognition to decline across all of these modalities over time.
“PREVENT-AD is one of the most important multi-modal studies of cognitive decline to date. We’re proud to be working with EyeThree on developing a predictive biomarker for Alzheimer’s dementia.”
Nathan Spreng, PhD · PI, PREVENT-AD · Montreal Neurological Institute
A single scan reads the circuits these conditions share, so the platform extends across indications instead of being built one disease at a time. We prioritize where a measurable neural signal is most actionable for treatment — and we disclose the evidence basis for each indication.
On standard 3T MRI. The method behind every EyeThree scan.
So each finding can be traced, checked, and reproduced.